Is biotech taking a trip to the world of psychedelic drugs? Why is Novo Nordisk going after Eli Lilly’s Zepbound ads? And what are peptides? 

This week on "The Top Line," Fierce's Zoey Becker, Will Maddox and Kevin Dunleavy chat about some of the biggest recent stories. From a psychedelics acquisition that could spark more movement in the emerging field to an advisory committee meeting on peptides shrouded in political controversy to a lawsuit between the two major obesity drugmakers, we’ll catch you up on the latest developments shaking up the biopharma world.

To learn more about the topics in this episode: 
‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelics 
UPDATE: Peptides favored on 1st day of closely watched FDA compounding adcomm
Peptide adcomm Day 2: Emideltide voted down in panel's 1st pushback
Novo Nordisk files lawsuit accusing rival Eli Lilly of running ‘false and misleading’ GLP-1 ads 
Novo escalates Lilly false advertising suit with planned bid to halt comparative ads 

Is biotech taking a trip to the world of psychedelic drugs? Why is Novo Nordisk going after Eli Lilly&rsquo;s Zepbound ads? And what are peptides?&nbsp;
This week on "The Top Line," Fierce's Zoey Becker, Will Maddox and Kevin Dunleavy chat about some of the biggest recent stories. From a psychedelics acquisition that could spark more movement in the emerging field to an advisory committee meeting on peptides shrouded in political controversy to a lawsuit between the two major obesity drugmakers, we&rsquo;ll catch you up on the latest developments shaking up the biopharma world.
To learn more about the topics in this episode:&nbsp;
<ul>
<li><a href="https://www.fiercebiotech.com/biotech/rising-tide-scenario-why-other-big-pharmas-could-follow-lilly-psychedelics" aria-label="Link &lsquo;A rising tide scenario&rsquo;: Why other Big Pharmas could follow Lilly into psychedelics">&lsquo;A rising tide scenario&rsquo;: Why other Big Pharmas could follow Lilly into psychedelics</a>&nbsp;</li>
<li><a href="https://www.fiercepharma.com/pharma/fda-adcomm-advisers-recommend-removal-restrictions-1st-7-peptides" aria-label="Link UPDATE: Peptides favored on 1st day of closely watched FDA compounding adcomm">UPDATE: Peptides favored on 1st day of closely watched FDA compounding adcomm</a></li>
<li><a href="https://www.fiercepharma.com/pharma/peptide-adcomm-day-2-emideltide-voted-down-panels-1st-peptide-pushback" aria-label="Link Peptide adcomm Day 2: Emideltide voted down in panel's 1st pushback">Peptide adcomm Day 2: Emideltide voted down in panel's 1st pushback</a></li>
<li><a href="https://www.fiercepharma.com/marketing/novo-accuses-lilly-running-false-and-misleading-glp-1-ads" aria-label="Link Novo Nordisk files lawsuit accusing rival Eli Lilly of running &lsquo;false and misleading&rsquo; GLP-1 ads">Novo Nordisk files lawsuit accusing rival Eli Lilly of running &lsquo;false and misleading&rsquo; GLP-1 ads</a>&nbsp;</li>
<li><a href="https://www.fiercepharma.com/marketing/novo-turns-heat-lilly-false-advertising-suit-seeking-preliminary-injunction-stop-rivals" aria-label="Link Novo escalates Lilly false advertising suit with planned bid to halt comparative ads">Novo escalates Lilly false advertising suit with planned bid to halt comparative ads</a>&nbsp;</li>
</ul>

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;